Tag Archives: health

EU Webinar Series: From Discovery to Decision Making Early-Stage Life Science Legible to Capital 

3 Mar

By Greg Mannix, VP, EMEA Business Development, LSN

Life Science Nation’s EU-focused webinar series, From Discovery to Decision: Making Early-Stage Life Science Legible to Capital, continues this week with Session III. Recordings of the first two sessions are available for those who would like to revisit the insights shared by active investors shaping early-stage healthcare financing.

This series examines a central question for early-stage companies: why strong science alone is not enough to secure capital, and how founders can structure development to become legible to investors.

Session I

Why Solid Science Fails to Translate Before Capital Even Considers It

Hosted by Richard Berenson, Managing Partner, Venzyme Catalyst

Watch the recording:
https://youtu.be/ODbukG6cjNM?si=9lj-BGKRhv2wJISW

In Session I, Richard Berenson offered a candid investor perspective on why many early-stage assets stall before diligence begins. He emphasized that the issue is often not a shortage of capital, but a failure of translation.

Scientific merit alone does not make an opportunity investable. Investors must see clarity around risk reduction, defined milestones, regulatory trajectory, and capital deployment strategy. Companies that struggle to articulate this framework may be filtered out long before meaningful evaluation takes place.

The discussion reframed from fundraising challenges as structural alignment issues rather than capital scarcity.

Session II

Legibility, Signal, and the Real Work Between Seed and Series B

Hosted by Karim Galzhar, Partner, OKG Capital

Watch the recording:
https://youtu.be/Dak112sslq4?si=9MpLvecop5Jxw4_E

Session II built on this foundation with a deeper examination of how investors form conviction between Seed and Series B.

Karim Galzhar outlined what global investors require to underwrite early-stage risk. Signals are formed across scientific validation, regulatory planning, commercial strategy, and disciplined capital use. Data alone does not create signals. Structured progress and stage-appropriate positioning.

The session highlighted how companies can unintentionally dilute signals by engaging the wrong forums too early or by misaligning fundraising expectations with development readiness.

Session III — This Wednesday

Partnering Is Not Exposure. It Is Filtration

Wednesday, March 4 | 10:00 AM ET / 4:00 PM CET

Session III will feature Dennis Ford, Founder & CEO of Life Science Nation and creator of the RESI Conference Series, alongside Gregory Mannix, VP, International Business Development, Life Science Nation.

This session confronts a simple truth: great science does not raise capital, signal does. We will examine how investors actually price risk, why fundraising must be run as a disciplined global campaign, and how legibility turns complex science into an investable story.

We will also address a costly mistake: engaging the wrong partnering events and the wrong investors too early. Not every conference, forum, or investor fits every stage of development. Success requires selecting the right venues, building a stage-appropriate global target list, and engaging partners who are structurally aligned with your product. The goal is to replace activity with real transaction momentum.

Registration for Session III is open: https://us02web.zoom.us/webinar/register/WN_oe499TEOQGmrSnoAzNr1yw#/registration

Register for RESI Europe

Tags: , , , , , , , , , ,

Novotech at RESI JPM: Strategic Early Clinical Development for Biotech Sponsors 

3 Mar

As a sponsor of RESI JPM, Novotech joined the RESI community during JPM Week to engage with emerging biotech companies at pivotal stages of development. Marina Mullins, VP of Early Clinical Development at Novotech, shared insight into the company’s biotech-focused model, global execution strategy, and evolving approach to early-phase clinical development. 

Marina Mullins
 CaitiCaitlin Dolegowski

Caitlin Dolegowski (CD): Can you briefly describe Novotech’s mission and core capabilities as a global CRO and scientific advisory partner? 

Marina Mullins(MM) : Novotech is a global full-service clinical research organization and scientific advisory partner focused on accelerating the development of innovative therapeutics for biotech and small- to mid-sized pharmaceutical companies. The company provides integrated clinical trial services across Phase I–IV, with particular strength in early clinical development, regulatory strategy, medical oversight, biometrics, and operational execution. 

With offices across Asia-Pacific, North America, and Europe, and long-standing site partnerships globally, Novotech combines regional expertise with global coordination to support sponsors from preclinical planning through proof-of-concept and beyond. Its model integrates scientific advisory and operational delivery, enabling sponsors to move efficiently from strategy to execution. 

CD: What differentiates Novotech from other CROs in terms of clinical execution, expertise, or client support? 

MM: Novotech differentiates itself through a biotech-centric approach and deep regional execution expertise. Rather than operating as a transactional service provider, the company works as a strategic partner, aligning development strategy with operational planning from the outset. 

Key differentiators include strong early-phase capabilities, particularly in first-in-human and proof-of-concept studies; deep regulatory and operational experience across high-performance regions such as Australia, Asia, and North America; therapeutic expertise spanning oncology, infectious diseases, obesity, CNS, endocrine, rare diseases, and emerging modalities; and a partnership model designed to provide agility, senior oversight, and milestone-aligned execution. 

This integrated structure allows sponsors to make data-driven decisions while maintaining timeline discipline and regulatory alignment. 

CD: How does Novotech’s global footprint support biotech and pharma companies as they advance clinical development? 

MM: Novotech’s global presence enables sponsors to strategically select development regions based on speed, regulatory pathway, patient access, and capital efficiency. 

For example, Australia offers an established regulatory framework that allows certain first-in-human studies to proceed under the Clinical Trial Notification scheme without requiring an Investigational New Drug submission to the U.S. Food and Drug Administration. This can provide an efficient pathway to first patient while maintaining internationally recognized ethical and regulatory standards. 

At the same time, Novotech’s footprint across Asia, North America, and Europe supports seamless program expansion into multi-regional trials. Sponsors benefit from consistent governance, harmonized data standards, and coordinated regulatory strategy as programs advance. 

CD: As a sponsor of RESI during JPM Week, what were your key objectives for participating this year? 

MM: Novotech’s objectives were centered on early engagement and strategic dialogue. The company aimed to connect with emerging biotech companies preparing for first-in-human or proof-of-concept studies, provide guidance on early development strategy and regulatory pathways, explore long-term partnerships beyond single studies, and support investor-backed companies in aligning clinical milestones with financing objectives. 

RESI provided a focused environment to engage with innovative sponsors at critical inflection points in development. 

CD: Who is Novotech most interested in connecting with? 

MM: Novotech is particularly interested in engaging with early- to mid-stage biotech companies transitioning from preclinical to first-in-human studies, and companies seeking an integrated CRO partner that combines regulatory advisory, scientific strategy, and operational execution. The emphasis is on building strategic relationships with sponsors who value early alignment between scientific design, regulatory positioning, and clinical operations. 

CD: Are there particular trends in early clinical development shaping Novotech’s ECD strategy? 

MM: Regulators are placing greater emphasis on optimized dose selection and robust early-phase data packages, increasing the use of adaptive designs, expansion cohorts, and integrated pharmacokinetic and pharmacodynamic modeling in first-in-human studies. 

There is also growing strategic use of healthy volunteer studies, where scientifically appropriate, to better characterize safety, pharmacokinetics, and target engagement before patient expansion. This can reduce downstream risk and improve capital efficiency. 

Biotech sponsors are under pressure to generate milestone-defining data efficiently. As a result, early programs increasingly incorporate translational biomarkers, seamless SAD and MAD structures, and optional proof-of-concept expansion pathways within unified protocol frameworks. 

Together, these trends reinforce a shift toward positioning early clinical development as a strategic foundation for the entire program lifecycle. 

Interested in sponsoring an upcoming RESI conference? 

To explore sponsorship opportunities, please contact resi@lifesciencenation.com. Life Science Nation would welcome the opportunity to meet and discuss organizational goals for connecting with the global RESI investor and innovator community.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Hot Investor Mandate: Family Office Backed Firm Seeks to Invest in Therapeutics, Especially Rare Diseases and Areas of Unmet Medical Need

3 Mar

The firm is a family-run investment and commercialization vehicle focused on early-stage life sciences and technology opportunities. The firm is flexible in structuring transactions, with prior investments ranging from minority participation in financing rounds to in-licensing entire therapeutic programs.  

The firm specializes in therapeutic opportunities, with a particular emphasis on rare diseases. The firm prioritizes indications where the pathophysiology is well understood, the development pathway is straightforward, and there is a clearly defined unmet medical need. The firm is also attracted to opportunities that are de-risked, including reformulation strategies and drug repurposing approaches.  

From a company and management team perspective, the firm has a strong preference for experienced leadership teams with proven track records of value creation and execution.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Cross-Border VC Firm With New Early-Stage Fund Invests in Biotech, Medtech, and Enabling Platforms in North America and Asia

3 Mar

 
 The firm is a global venture capital firm headquartered in Asia, with investment activity spanning Asia and the United States. The firm has raised multiple funds and recently launched a dedicated vehicle focused on biotechnology and medical technology innovation. The firm invests from Seed through early-growth stages and has backed a broad portfolio of healthcare companies. The firm deploys equity capital and works closely with founders to support global expansion, leveraging cross-border operating presence and networks across Asia and North America.  

The firm focuses on biotechnology, medical technology, and enabling platforms addressing major unmet needs in human health. The firm invests in breakthrough science and engineering-driven innovation, including therapeutics, medtech devices, diagnostics, digital health, research tools, and frontier health technologies. The firm follows a cross-border strategy that sources scientific breakthroughs from both Eastern and Western ecosystems, particularly opportunities facing market fragmentation or structural barriers that may limit global scale. The firm emphasizes companies with strong scientific foundations, differentiated clinical or technical positioning, and opportunities that can benefit from accelerated development and market access through Asian clinical, talent, and supply chain ecosystems.  

From a company and management team perspective, the firm partners with founders who demonstrate deep scientific or medical expertise, strong execution capability, and readiness for global expansion. The firm actively supports teams through hands-on venture building and provides access to clinical resources, supply networks, operating talent, and cross-border strategic guidance. The firm collaborates with companies from early stages through exit, aligning with founders to pursue global outcomes including IPOs, M&A, and strategic partnerships. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Family Office Invests in Pre-Clinical and Clinical Stage Biotech and Tech-Enabled Healthcare Technologies in North America

3 Mar

A family office invests in both private and public life science and healthcare companies. The firm typically writes six-figure checks for companies approaching clinical development. While historically focused on North America, the firm remains open to evaluating opportunities globally. The firm invests across therapeutics, diagnostics, digital health, and medical devices.  

The firm is generally disease-agnostic, with particular interest in ophthalmology, inflammation, and dermatology. The firm is also increasingly exploring opportunities at the intersection of technology and healthcare, including AI-enabled platforms that enhance patient management and diagnostic workflows. Although oncology is not a core focus, the firm may selectively evaluate certain indications.  

From a stage perspective, the firm reviews opportunities as early as pre-IND and generally prefers programs through Phase II development. The firm seeks evidence of technical and regulatory de-risking, including proof-of-concept data, early efficacy signals, and clearly defined regulatory pathways.  

The firm does not impose strict requirements on company or management team composition but values teams that demonstrate regulatory expertise and the ability to execute within clinical and compliance-driven environments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global Biopharmaceutical Seeks Strategic Investment and Partnering Opportunities With Early-Stage Therapeutics Assets

3 Mar

The firm is a publicly listed global biopharmaceutical company headquartered in Asia with a strong presence across major international markets. The firm is recognized for its capabilities in large-scale biologics development and manufacturing and has built a substantial commercial footprint worldwide. The firm pursues external innovation through equity investments, research collaborations, and in-licensing arrangements to strengthen and diversify its pipeline.  

The firm operates broadly across therapeutics and biopharmaceutical innovation, with established expertise in antibody-based medicines, follow-on biologics, and next-generation biologic platforms. The firm continues to expand into novel therapeutic programs across immunology, oncology, infectious diseases, and other high-need areas. In addition to maintaining a portfolio of established biologic products, the firm is actively enhancing its innovative pipeline through internal research, strategic partnerships, and selective in-licensing of differentiated biologic assets, including immune-modulating therapies and advanced antibody formats. The firm is open to opportunities across development stages, with interest in early and mid-stage programs.  

The firm seeks partnerships that align with its long-term biologics strategy and leverage its global development, regulatory, and manufacturing infrastructure. The firm evaluates opportunities based on strong scientific rationale, differentiated clinical positioning, scalable manufacturing feasibility, and global market potential. The firm prefers to collaborate with teams that demonstrate rigorous data generation, defensible intellectual property, and the operational capability to execute international development and commercialization strategies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

RESI Europe Partnering Opens March 2: Secure Investor Meetings Early and Bring a Complimentary Second Attendee

24 Feb

By Greg Mannix, VP, EMEA Business Development, LSN

As RESI Europe 2026 approaches, one of the most important milestones is just ahead. On March 2, the partnering platform officially opens, giving registered attendees the opportunity to begin requesting and scheduling meetings with investors, strategic partners, and fellow innovators across the global life science ecosystem.

Below are two key updates to plan around.

Partnering Opens March 2: Secure Meetings Early

Partnering is the foundation of every RESI conference. From the moment the platform opens, companies can review attendee profiles, identify aligned investors and strategic partners, and begin building a focused meeting schedule.

The earlier you register and enter the platform, the more time you can:

  • Refine your profile and messaging
  • Target investors who match your stage and sector
  • Send thoughtful, customized meeting requests
  • Fill your calendar with high-value conversations

RESI Europe is structured to help early-stage companies connect efficiently with active investors. Through curated matchmaking and detailed attendee profiles, startups can prioritize fit over volume. Beyond pre-scheduled 1-to-1 meetings, the conference also creates opportunities for ad hoc introductions and follow-up discussions that often extend well beyond the event itself.

To help attendees prepare, Life Science Nation will host a dedicated RESI Europe Partnering Tutorial on Tuesday, March 3 at 10:00 AM Eastern Time (US and Canada). Understanding the RESI partnering system and using it to its maximum capabilities can make a significant difference in a company’s success at RESI Europe 2026. During this session, LSN staff will walk participants through how to navigate the platform, identify investors and strategic partners who are the best fit, manage outreach effectively, implement a strong follow-up strategy, and leverage the full range of conference content to strengthen their overall partnering experience. You can register for the webinar here.

Complimentary Second Attendee with 5-Day Registration

To help companies maximize their partnering coverage, RESI Europe 2026 is offering a complimentary second attendee pass with a standard 5-day registration.

Bringing a colleague allows your team to:

  • Cover more investor meetings
  • Attend concurrent sessions
  • Expand networking reach across the event
  • Ensure no key conversation is missed

This offer is not valid for Virtual or Audience Access passes. Attendees who registered for a 5-day ticket on or before February 22 may contact salescore@lifesciencenation.com to add a second attendee.

With partnering opening March 2 and expanded registration value now available, now is the time to secure your place. Enter the partnering system early, prepare strategically, and position your company to make the most of RESI Europe 2026.

Register for RESI Europe

Tags: , , , , , , , , , ,

← Older Entries
Newer Entries →